STOCK TITAN

NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on developing treatments for brain and central nervous system cancers, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.

Interested investors can arrange one-on-one meetings with the company's management team through their BTIG representative or by contacting James@HaydenIR.com.

NeOnc Technologies (NASDAQ: NTHI), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di trattamenti per tumori al cervello e al sistema nervoso centrale, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale di Biotecnologia BTIG prevista per il 29-30 luglio 2025.

Gli investitori interessati possono organizzare incontri individuali con il team dirigenziale dell'azienda tramite il loro rappresentante BTIG o contattando James@HaydenIR.com.

NeOnc Technologies (NASDAQ: NTHI), una compañía biotecnológica en etapa clínica enfocada en desarrollar tratamientos para cánceres del cerebro y del sistema nervioso central, ha anunciado su participación en la próxima Conferencia Virtual de Biotecnología BTIG programada para el 29-30 de julio de 2025.

Los inversores interesados pueden concertar reuniones individuales con el equipo directivo de la empresa a través de su representante de BTIG o contactando a James@HaydenIR.com.

NeOnc Technologies (NASDAQ: NTHI)는 뇌 및 중추신경계 암 치료제 개발에 주력하는 임상 단계 생명공학 기업으로, 2025년 7월 29일부터 30일까지 예정된 BTIG 가상 바이오테크 컨퍼런스에 참여한다고 발표했습니다.

관심 있는 투자자들은 BTIG 담당자나 James@HaydenIR.com으로 연락하여 회사 경영진과 1:1 미팅을 예약할 수 있습니다.

NeOnc Technologies (NASDAQ : NTHI), une entreprise biotechnologique en phase clinique spécialisée dans le développement de traitements contre les cancers du cerveau et du système nerveux central, a annoncé sa participation à la prochaine Conférence virtuelle BTIG sur la biotechnologie prévue les 29 et 30 juillet 2025.

Les investisseurs intéressés peuvent organiser des réunions individuelles avec l'équipe de direction de la société via leur représentant BTIG ou en contactant James@HaydenIR.com.

NeOnc Technologies (NASDAQ: NTHI), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Behandlungen für Hirn- und zentrale Nervensystemkrebs spezialisiert hat, hat seine Teilnahme an der kommenden BTIG Virtual Biotechnology Conference angekündigt, die für den 29.-30. Juli 2025 geplant ist.

Interessierte Investoren können Einzelgespräche mit dem Management-Team des Unternehmens über ihren BTIG-Vertreter oder durch Kontaktaufnahme mit James@HaydenIR.com vereinbaren.

Positive
  • None.
Negative
  • None.

CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.

Investors interested in scheduling a 1x1 meeting with management are invited to contact their BTIG representative directly or reach out to James@HaydenIR.com

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit neonc.com.

Important Cautions Regarding Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.

Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.

The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.

We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact:
info@neonc.com

Investor Contact:


James Carbonara

Hayden IR

(646)-755-7412

James@haydenir.com


FAQ

When is NeOnc Technologies (NTHI) participating in the BTIG Virtual Biotechnology Conference?

NeOnc Technologies will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025.

How can investors schedule meetings with NeOnc Technologies (NTHI) management at the BTIG conference?

Investors can schedule 1x1 meetings by contacting their BTIG representative or by emailing James@HaydenIR.com.

What type of company is NeOnc Technologies (NTHI)?

NeOnc Technologies is a clinical-stage biotechnology company that develops treatments for brain and central nervous system cancers.

Where will the BTIG Biotechnology Conference with NeOnc Technologies (NTHI) be held?

The BTIG Biotechnology Conference will be held virtually.
NeOnc Technologies Holdings Inc

NASDAQ:NTHI

NTHI Rankings

NTHI Latest News

NTHI Latest SEC Filings

NTHI Stock Data

102.93M
2.10M
Pharmaceutical Preparations
CALABASAS